<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: Humanin (HN) is a 24-amino acid <z:chebi fb="7" ids="16670">peptide</z:chebi> best known for its ability to protect neurons from damage caused by <z:hpo ids='HP_0002511'>Alzheimer disease</z:hpo>-related proteins </plain></SENT>
<SENT sid="1" pm="."><plain>This study examines the neuroprotective effects of HNG (a potent form of HN) on focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>/reperfusion injury in mice </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Mice underwent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> for 75 minutes followed by 24-hour reperfusion </plain></SENT>
<SENT sid="3" pm="."><plain>Mice were pretreated with 0.1 microg HNG (intracerebroventricularly) 30 minutes before <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>; posttreated at 0, 2, 4, and 6 hours after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>; or pretreated with 1 microg HNG (intraperitoneally) 1 hour before <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Neurological deficits and cerebral <z:mpath ids='MPATH_124'>infarct</z:mpath> volume were evaluated </plain></SENT>
<SENT sid="5" pm="."><plain>Neuronal <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and activated poly(<z:chebi fb="13" ids="16761">ADP</z:chebi>-<z:chebi fb="1" ids="33942">ribose</z:chebi>) polymerase expression were measured by TUNEL and Western blot analysis, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>Activated ERKs were examined by Western blot analysis </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: Pretreatment with 0.1 microg HNG (intracerebroventricularly) 30 minutes before <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> reduced cerebral <z:mpath ids='MPATH_124'>infarct</z:mpath> volume from 56.2+/-3.0% to 26.1+/-1.4% (P&lt;0.01) </plain></SENT>
<SENT sid="8" pm="."><plain>HNG posttreatment after 4 hours of reperfusion reduced cerebral <z:mpath ids='MPATH_124'>infarct</z:mpath> volume to 45.6+/-2.6% (P&lt;0.05) </plain></SENT>
<SENT sid="9" pm="."><plain>Pretreatment with 1 microg HNG (intraperitoneally) 1 hour before <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> or posttreatment after 2 hours of reperfusion reduced cerebral <z:mpath ids='MPATH_124'>infarct</z:mpath> volume significantly </plain></SENT>
<SENT sid="10" pm="."><plain>HNG also significantly improved neurological function and inhibited both neuronal <z:mpath ids='MPATH_3'>apoptosis</z:mpath> as well as poly(<z:chebi fb="13" ids="16761">ADP</z:chebi>-<z:chebi fb="1" ids="33942">ribose</z:chebi>) polymerase activation </plain></SENT>
<SENT sid="11" pm="."><plain>A significant decrease of phospho-ERK was observed in mice treated with HNG, whereas phospho-JNK and phospho-p38 levels were not altered </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: Our results demonstrate that HNG protects against <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>/reperfusion injury in mice </plain></SENT>
<SENT sid="13" pm="."><plain>HNG offers neuroprotection in vivo at least in part by inhibiting ERK activation </plain></SENT>
<SENT sid="14" pm="."><plain>These findings suggest a potential therapeutic role for HNG in the treatment of <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
</text></document>